Semaglutide for Fatty Liver Disease (MASH/NAFLD): Complete Guide to the ESSENCE Trial and FDA Approval

Fatty liver disease has quietly become one of the most common chronic liver conditions in the world — and for decades, patients had no approved treatments beyond lifestyle changes. That changed in 2024 and 2025, as two landmark drug approvals gave clinicians new weapons against a disease affecting tens of millions of Americans. Among them: semaglutide 2.4 mg weekly, a GLP-1 receptor agonist now FDA-approved for metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis.

This guide covers the science, the ESSENCE Phase 3 trial data, the dosing protocol, side effects, and who stands to benefit most.

What Is MASH and How Common Is It?

You may know it by older names: nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). In 2023, international liver societies updated the nomenclature to better reflect the metabolic roots of the disease:

• MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease) — replaces NAFLD; refers to excess fat in the liver tied to metabolic risk factors
• MASH (Metabolic dysfunction-Associated Steatohepatitis) — replaces NASH; the severe inflammatory form that can progress to fibrosis, cirrhosis, and liver failure

The numbers are staggering. An estimated 25–30% of U.S. adults live with MASLD. Approximately 22 million Americans have MASH, and nearly 9 million have clinically significant liver fibrosis (stages F2–F3). Projections show MASH cases climbing from 14.9 million in 2020 to 23.2 million by 2050 as obesity and type 2 diabetes rates continue to rise.

MASH is not benign. Without treatment, it can progress through four fibrosis stages to cirrhosis, end-stage liver disease, and hepatocellular carcinoma. It is already one of the leading indications for liver transplant in the U.S.

How GLP-1 Agonists Work in the Liver

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, best known for treating type 2 diabetes (Ozempic) and obesity (Wegovy). But its effects extend well beyond blood sugar and appetite — and the liver is a key target.

GLP-1 receptors have been identified on human hepatocytes. When activated, they trigger several protective pathways:

• Reduced de novo lipogenesis — less fat production within the liver
• Enhanced mitochondrial beta-oxidation — increased burning of free fatty acids
• Decreased hepatic insulin resistance — improved insulin signaling in liver tissue
• Anti-inflammatory effects — reduced cytokine activity driving hepatic inflammation
• Anti-fibrotic signaling — modulation of pathways that promote scar tissue formation

Beyond direct hepatic effects, semaglutide produces significant systemic weight loss — and even modest body weight reductions of 5–10% are known to improve liver histology in MASH patients. The combination of direct and indirect mechanisms makes GLP-1 agonists uniquely suited to MASH's multifactorial nature.

The ESSENCE Phase 3 Trial: Results

The pivotal evidence for semaglutide in MASH comes from the ESSENCE trial — a Phase 3, randomized, placebo-controlled study. Results were presented at the AASLD Liver Meeting in November 2024 and published in the New England Journal of Medicine.

The trial enrolled adults with biopsy-confirmed MASH and liver fibrosis stages F2 or F3. Participants received semaglutide 2.4 mg weekly or placebo for 72 weeks.

Co-Primary Endpoints at 72 Weeks

• Steatohepatitis resolution with no worsening of fibrosis: 62.9% (semaglutide, n=534) vs. 34.3% (placebo, n=266) — a difference of 28.7 percentage points
• Fibrosis reduction with no worsening of steatohepatitis: 36.8% vs. 22.4% — a difference of 14.4 percentage points

Secondary Outcomes

• Body weight change: −10.5% (semaglutide) vs. −2.0% (placebo)
• Liver enzymes: Significant reductions in ALT and AST
• Liver fat: Meaningful reductions detectable as early as 3 months and sustained through 52+ weeks

The 62.9% steatohepatitis resolution rate is particularly remarkable — a level of histologic improvement previously associated only with bariatric surgery or intensive lifestyle interventions.

FDA Approval: What Was Approved and When

On August 15, 2025, the FDA granted approval for semaglutide 2.4 mg weekly (Wegovy) as a treatment for adults with MASH and moderate to advanced liver fibrosis (stages F2–F3). This made semaglutide the first GLP-1 receptor agonist approved for a liver disease indication in the U.S.

The approval covers adults with biopsy-confirmed or noninvasively diagnosed MASH with significant fibrosis — a population of roughly 9 million Americans who previously had no targeted pharmacological options.

Dosing Protocol

The dosing regimen used in ESSENCE follows the same titration schedule as Wegovy for obesity:

1. Weeks 1–4: 0.25 mg subcutaneously once weekly
2. Weeks 5–8: 0.5 mg once weekly
3. Weeks 9–12: 1.0 mg once weekly
4. Weeks 13–16: 1.7 mg once weekly
5. Week 17 onward: 2.4 mg once weekly (target maintenance dose)

In the ESSENCE trial, 88% of participants maintained the 2.4 mg target dose at week 72. For those who cannot tolerate the full dose, staying at a lower dose level is acceptable — efficacy is preserved to a degree at lower doses.

The injection is administered subcutaneously in the abdomen, thigh, or upper arm using the same pen device as Wegovy.

Side Effects and Safety Considerations

The safety profile of semaglutide in ESSENCE was consistent with its established profile in weight management and diabetes:

Common (GI-Related)

• Nausea — most common; typically mild and transient
• Diarrhea
• Constipation
• Vomiting

GI side effects peak during dose escalation and generally resolve with continued use. Eating smaller meals and slowing the titration schedule can help.

Less Common But Important

• Gallbladder disease — weight loss increases gallstone risk; monitor for biliary symptoms
• Acute pancreatitis — rare; discontinue if suspected
• Acute kidney injury — secondary to dehydration; ensure adequate hydration
• Thyroid C-cell tumors — theoretical risk from rodent data; contraindicated in patients with medullary thyroid carcinoma history or MEN2
• Lean mass loss — significant weight loss may include muscle; resistance exercise and protein intake are recommended
• Retinopathy worsening — rare; monitor patients with pre-existing diabetic retinopathy

Semaglutide vs. Resmetirom (Rezdiffra)

Resmetirom (Rezdiffra), a thyroid hormone receptor beta (THR-β) agonist, received FDA approval in March 2024 — making it the first-ever approved MASH therapy. Understanding the differences between the two drugs matters for clinical decision-making.

Semaglutide's higher resolution rate is striking, though direct comparisons carry caveats since trials enrolled different patient populations. Their complementary mechanisms have sparked interest in combination therapy — currently under investigation.

Patients with obesity, insulin resistance, or type 2 diabetes may benefit particularly from semaglutide's broader metabolic reach. Resmetirom may suit patients preferring a daily pill, those with limited weight loss goals, or those with contraindications to GLP-1 therapy.

Who Is a Good Candidate for Semaglutide?

The FDA approval covers adults with MASH and fibrosis stages F2–F3. Clinically, semaglutide tends to be a particularly good fit for patients who:

• Are overweight or obese (BMI ≥27) and would benefit from weight loss
• Have type 2 diabetes or prediabetes — common MASH comorbidities that semaglutide addresses simultaneously
• Have elevated cardiovascular risk — semaglutide has proven CV outcome data (SELECT trial)
• Prefer once-weekly injection over a daily oral pill

Semaglutide is not appropriate for:

• Patients with cirrhosis (F4 fibrosis) — excluded from ESSENCE
• Personal or family history of medullary thyroid carcinoma or MEN2
• Pregnancy or planned pregnancy
• Severe GI motility disorders such as gastroparesis

Fibrosis stage is typically confirmed by liver biopsy or noninvasive methods including elastography (FibroScan), MRI-PDFF, or serum biomarker panels (FIB-4, ELF score).

What Comes Next

The ESSENCE trial continues with longer-term follow-up beyond the 72-week Part 1 analysis. Researchers are evaluating whether sustained semaglutide treatment can prevent progression to cirrhosis, improve all-cause mortality, or reduce liver transplant rates — the outcomes that will ultimately define its place in MASH management.

Ongoing studies are also investigating semaglutide in compensated cirrhosis (F4) and the potential synergy of combining semaglutide with resmetirom for patients who achieve partial response on monotherapy.

Conclusion

Semaglutide 2.4 mg weekly is now a fully FDA-approved treatment for MASH with moderate to advanced liver fibrosis — the second approved MASH therapy and the first in the GLP-1 class. The ESSENCE Phase 3 trial showed a 62.9% rate of steatohepatitis resolution at 72 weeks, nearly double the placebo rate, along with significant fibrosis reduction and meaningful weight loss.

For the millions of Americans living with MASH — particularly those with obesity, type 2 diabetes, or metabolic syndrome — semaglutide offers a compelling, evidence-backed treatment option that addresses the liver and its metabolic drivers simultaneously.

If you have been diagnosed with fatty liver disease, MASH, or significant liver fibrosis, speak with a hepatologist or gastroenterologist about whether semaglutide or other approved therapies are appropriate for your situation.

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication.